Annual Meeting 2020 - Online Program 2 October
Amsterdam Neuroscience decided to change the familiar face-to-face celebration of our Annual Meeting and host an online event to connect with the Amsterdam Neuroscience network in 2020. This online Annual Meeting will bring together the neuroscientists and clinicians of Amsterdam UMC, Vrije Universiteit Amsterdam and University of Amsterdam. The day will provide insight in the developments of neuroscience in the Amsterdam region. Read the online program below and register now.
11:00-12:30 Word of Welcome & Research Reports
Arjen Brussaard and Diederik van de Beek will open this year’s virtual edition of the Annual Meeting followed by four research reports.
- Gijs Kooij - (Re)solving MS: understand and exploit endogenous protection systems
- Marc Engelen - Quantifying disease severity in progressive neurometabolic disorders
- Linda Douw - BrainLayer: the multilayer brain networks underlying cognitive decline
- Mirjam van Zuiden - Towards Accurate Screening and Prevention (2-ASAP): improving early risk detection and indicated prevention for Posttraumatic Stress Disorder
13:30-15:00 Pecha Kucha
A selection of speakers from the nine research programs of Amsterdam Neuroscience will tell their scientific story with the familiar Pecha Kucha format. During this year’s virtual edition, the audience will help to decide who is the best Pecha Kucha presenter of 2020.
15:30-17:00 – Multimedial Swammerdam Presentation by Hilgo Bruining and colleagues
Transforming treatments for neurodevelopmental disorders into solid N-of-1 trials
Current treatments for neurodevelopmental disorders are diagnosis-driven with unpredictable efficacy and side effects. Failed conventional trials cause increasing despair among patients and caregivers. A paradigm shift from one-size-fits-all to a tailored and personalized approach is urgently needed. This year’s Swammerdam presentation outlines how the NWA supported NewTDec* consortium takes on this challenge to inform, perform and monitor rational treatments at the patient ‘n-of-1’ level. The consortium exemplifies team science focused at the integration of various model-driven and data-driven approaches needed for precision therapy in neurodevelopmental disorders. This presentation will follow the transformation towards a n-of-1 approach supported by real life decisions and stories from the patients and caregiver’s perspective.
*New, rational therapy decisions for developmental brain disorders: Integrating quantitative patient assessment, cellular assays and nanotechnology.
Klaus Linkenkaer-Hansen, Niels Cornelisse, and Bas Stunnenberg will contribute to this presentation.